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Abstract 
The present study was undertaken with an aim to formulation development 
and evaluation of gastroretentive mucoadhesive sustained release tablet of 
Venlafaxine hydrochloride which releases the drug in a sustained manner 
over a period of 12 hours, by using Carbopol 971P  in combination with  
eudragit RS-PO and ethyl cellulose as a mucoadhesive and release retardant 
respectively. Preformulation study was done initially and results directed for 
the further course of formulation. Based on Preformulation studies different 
batches of Venlafaxine hydrochloride were prepared using Carbopol 971P, 
Eudragit RS-PO and ethyl cellulose chosen for their different hydrophilic 
properties to calculate the sustained release properties. Sustained release 
tablets were prepared by direct compression and were evaluated for 
bioadhesion time, swelling index and matrix erosion, and in vitro drug 
release. The tablets of batch F3 and F6 had high swelling behaviors but 
release of drug is very less.  And batch F2 having considerable swelling 
index and in vitro drug release (99.85%). Batch F2 can be taken as an ideal or 
optimized formulation of sustained release tablets for 12 hour release as it 
fulfills all the requirements for sustained release tablet. From the discussion it 
is concluded that use of carbopol as a release retardant and adhesive polymer 
is very effective; and also it act as strong release retardant in combination 
with hydrophobic polymers.   
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Introduction  
Venlafaxine is a unique antidepressant, and is referred 
to as a serotonin-norepinephrine-dopamine reuptake 
inhibitor [1]. It works by blocking the transporter 
reuptake proteins for key neurotransmitters affecting 
mood, thereby leaving more active neurotransmitter 
in the synapse [2]. Venlafaxine inhibit the neuronal 
uptake of norepinephrine, serotonin and to a lesser 
extent  dopamine,  but  have  no  monoamine  oxidase  
 
 
inhibitory activity and a low affinity for brain 
muscarinic, cholinergic, histaminergic or alpha-
adrenergic receptors [3]. Hence, it lacks the adverse 
anticholinergic, sedative and cardiovascular effects of 
tricyclic antidepressants [4]. The steady state half 
lives of venlafaxine are 5 hour, necessitating the 
administration, two or three times daily so as to 
maintain adequate plasma levels of drug. 
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The objective of this present study is to develop a 
Gastroretentive mucoadhesive sustained release tablet 
of venlafaxine hydrochloride which releases the drug 
in a sustained manner over a period of 12 hours, by 
using Carbopol 971P  and Eudragit RS-PO as a 
mucoadhesive and release retardant respectively.  
• To formulate the mucoadhesive sustained 
release dosage form of venlafaxine 
hydrochloride. 
• To study the effect of polymer concentration 
on tablet characteristic.  
• To study the effect of combination and 
composition of various polymer materials on 
tablet characteristic.  
• To study the effect of temperature and relative 
humidity on tablet characteristic.  
 
Materials and methods  
Materials 
Venlafaxine hydrochloride was provided by 
Wokhardt pharmaceutical Ltd (Aurangabad, India) 
and Sodium carboxymethylcellulose (Na CMC) and 
Dicalcium phosphate was a gift from Ajanta 
pharmaceutical Ltd Aurangabad, Eudragit-RS PO a 
gift sample from Glenmark pharmaceutical Ltd 
Nashik, and other materials are analytical grade. 
 
Methods 
Tablets were made by direct compression. All 
ingredients were weighed accurately and passed 
through 40 mesh sieve. Drug was mixed with 
excipients in geometric proportion for 15 min. 
Weighed quantities of DCP and magnesium stearate 
were passed through 40 mesh sieve and then blended 
with the above mass for 3 min. Compression was 
done on a as Rimek multistation tablet compressing 
machine fitted with flat punches and dies (13 mm 
diameter).   
 
Evaluation of tablets [5, 6, 7, 8]  
The compressed matrix tablets were evaluated for 
thickness, weight variation, hardness and drug 
content. 
 
Thickness 
The thickness of tablet was determined using Vernier 
Caliper (Kayco, India). Six tablets from each batch of 
formulation were used and mean thickness value and 
SD was calculated for each formulation. 
 
Hardness 
For each formulation, the hardness of six tablets was 
measured using the Pfizer hardness tester (Cadmach, 
Ahemadabad, India) and mean value and SD was 
calculated for each formulation. 
Weight variation: 
To study the weight variation, 20 tablets of each 
formulation were weighed using an electronic digital 
balance. The average weight of each tablet was 
calculated. 
 
Table 1. Formulation of venlafaxine HCl 
mucoadhesive tablets. 
 
Ingredients(mg) 
/Formulatiom F1 F2 F3 F4 F5 F6 
Venlafaxine HCL 150 150 150 150 150 150 
Carbopol971P 125 150 175 125 150 175 
Eudragit-RS PO 175 150 125 150 125 100 
Ethyl cellulose-cp7 - - - 50 50 50 
DCP 40 40 40 15 15 15 
Magnesium stearate 10 10 10 10 10 10 
 
Friability 
For each formulation the friability of 6 tablets was 
determined using Roche Friabilator (Remi 
Equipments). 
 
Drug content 
Five tablets were weighed and powdered. Weigh 
accurately a quantity of the powder equivalent to 0.1 
g of venlafaxine hydrochloride shake with 50 ml of 
1.2 pH for 10 minutes, and add sufficient 0.1N HCl to 
produce 100.0 ml and filter. After suitable dilution 
with solvent measure the absorbance of the resulting 
solution at the maximum at about 224.10 nm. 
Calculate the content of venlafaxine HCl, at the 
maximum at about 224.10 nm. 
 
Swelling study of formulations [9] 
Swelling study of individual polymers and 
combinations was carried out using USP type I 
dissolution apparatus (rotating paddle), DISSO 2000 
LABINDIA at 100 rpm and 0.1 N HCl was used as 
medium, temperature was maintained at 37± 0.50 C. 
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Weight of individual tablet was taken prior to the 
swelling study (W1). The tablet was kept in a basket. 
The weight of tablet was taken at time interval of 4, 8, 
12 hours (W2). Percent hydration (swelling index) 
was calculated as shown in table 4 using following 
formula, 
% of hydration = (W2-W1) X 100 / W2 
Where W1:- initial weight of tablet, W2:- weight of 
tablet after 12 hours. 
 
Table 2. Evaluation of venlafaxine HCl mucoadhesive tablets. 
 
Formulation 
Code 
Thickness (mm) 
(mean ±S.D) 
Hardness 
(Kg/cm2) 
(mean ±S.D) 
Weight 
Variation 
(%) 
Friability (%) 
(mean ±S.D) 
Drug 
Content (%) 
F1 4.05 ±0.0034 7.8±0.0011 2.2 0.48±0.0043 99.05 
F2 3.95 ±0.0012 8.00±0.0043 1.4 0.35±0.0023 100.03 
F3 3.90 ±0.0023 7.95±0.0022 1.5 0.40±32 98.25 
F4 4.00 ±0.0014 7.95±0.0015 1.8 0.41±0.0027 98.12 
F5 3.95 ±0.0030 8.05±0.0034 1.4 0.35±0.0028 99.38 
F6 3.9 ±0.0033 7.90±0.0020 2.5 0.42±0.0032 100.06 
 
Measurement of matrix erosion [9] 
The swollen tablet in swelling study at 12 hours was 
dried at 600 C for in vaccum oven. The tablet were air 
dried for 7 days and reweighed (W3). Matrix erosion 
or dissolution was calculated by using following 
formula, 
DS= (W1-W3) X 100 / W1 
Where, W1- initial weight of tablet, W3 = Weight of 
tablet dried at 600 C for 24 hrs in vacuum. 
 
In-vitro mucoadhesion measurement [10] 
Adhesion time of formulations were determined by 
using USP type VI (rotating cylinder method) 
apparatus, DISSO 2000 LABINDIA at 37 ± 0.50 C at 
100 rpm using 0.1N HCl as a medium. The goat 
gastric mucosa was adhered to the cylinder by using 
cynoacrylate glue. The Tablet was pressed on the 
mucosa gently with the finger for 1 minute. Time 
upto which Tablet remains adhered to goat gastric 
mucosa was measured and shown in table 3. 
 
In vitro drug release study [11, 12, 13]  
In vitro dissolution of formulation was studied using 
the rotating basket method (USP Type I apparatus). In 
this method, 900 ml of 0.1 N HCl was used as the 
dissolution media. The rate of stirring was 100 rpm. 
The tablets were placed in dissolution media 
maintained at 37 ± 5°C for a period of 12 hours. At 
appropriate time interval up to 12hrs, 5 ml of each 
sample was taken and 0.45 membranes filtered.  
 
Table 3. Adhesion time of venlafaxine HCl 
mucoadhesive tablets. 
 
Formulation Adhesion time in Hrs 
F1 9.30 
F2 12.00 
F3 12.00 
F4 10.35 
F5 10.42 
F6 12.05 
 
The dissolution media was then replaced by 5 ml of 
fresh dissolution fluid to maintain a constant volume 
(sink condition).  
 
Table 4. Swelling index of tablets. 
 
Percent swelling 
index in hours 
Formulation 
4 8 12 
% Matrix 
erosion or 
dissolution 
after 12 hours 
F1 23 39 48 24 
F2 29 43 59 27 
F3 32 46 61 31 
F4 24 40 47 24 
F5 31 44 58 29 
F6 31 45 61 30 
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Table 5. Drug release profile of mucoadhesive tablets. 
 
Time F1 F2 F3 F4 F5 F6 
1 42.42857 23 20.57143 18 23 23.28571 
2 48.80714 31.84206 33.1142 36.67143 31.12778 32.27222 
3 57.64841 42.16111 41.444 41.58889 44.3 42.73651 
4 55.39444 54.96508 51.24 53.24683 45.83016 48.40079 
5 64.84048 58.5754 56.807 57.25397 55.36746 52.38095 
6 68.432 64.30238 63.54762 64.85317 66.24206 58.09603 
7 72.14286 79.08175 73.60873 72.20714 69.74683 64.453 
8 79.40079 85.36984 79.15238 77.45714 75.4119 69.26984 
10 92.69683 91.21746 81.7246 80.01984 76.24921 73.93254 
12 107.4929 98.85397 90.7373 85.02302 83.3746 81.47619 
 
The amount of drug present in the samples was 
calculated with the help of calibration curve 
constructed. 
 
Result and discussion 
Evaluation of tablets 
The thickness of all the formulations were varies 
within ranges from 3.8 - 4.10 mm. All the formulation 
showed uniform thickness. The weight variation test 
was carried out as per official method and it was 
found that all formulation to be within the limit (as 
per pharmacopoeial standard). The content uniformity 
test was also carried out as per official method and it 
was found that different batches shown good content 
uniformity. It was found that all batches shown 
percent drug content more than 98 %. The tablet 
hardness of all the formulations was determined and it 
was found sufficient in the range 7.5-8.1 kg/cm2. 
Another measure of tablet hardness was the friability. 
A compressed tablet that loses less than 1% of their 
weight is generally considered acceptable. For all 
formulation tried here the weight loss was less than 
1% hence acceptable. 
 
In vitro bioadhesion time 
Adhesion time of formulations was shown in table 3. 
Formulation 2 and 3 shows adhesion time up to 12 
hours. Mucus turnover in humans is 12 hours. So 
formulations were designed to adhered mucosa up to 
12 hours. 
 
Swelling study and matrix erosion 
The percentage water uptake of the formulations (F1–
F6) at 12 hr ranged from 47 to 61 %, shown in table 
4.  
 
 
 
Figure 1. Drug release profile of formulation F1, 
F2 and F3. 
 
Because of hydrophilic nature of carbopol the 
percentage water uptake was found to be increased on 
increasing the concentration of carbopol. While the 
percentage matrix erosion was found to be increased 
with increasing the concentration of carbopol in the 
formulations because carbopol get dissolve in water 
giving stable colloidal dispersion and thereby eroded 
to a greater extent; and was found to be decreased on 
increasing the concentration of eudragit RSPO and 
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ethyl cellulose because hydrophobic nature of 
polymer forming barrier for swelling of carbopol. The 
drug release rate decreases with increasing the 
concentration of carbopol and ethyl cellulose. 
 
In vitro drug release study 
The drug release profile of formulation F1-F6 was 
shown in table 5. As the concentration of carbopol 
increases the drug release rate decreases due to high 
matrix gel formation. The drug release rate of 
formulation containing ethyl cellulose was less than 
formulation containing eudragit RSPO due to high 
hydrophobic nature of ethyl cellulose than eudragit 
RSPO which form strong barrier to restrict the 
swelling of carbopol and decrease the drug release 
rate.   
 
 
 
Figure 2. Drug release profile of F4, F5 and F6. 
 
Conclusion  
The prepared mucoadhesive tablets of Venlafaxine 
hydrochloride prepared and evaluated. The adhesion 
time of the batch F2, F3 and F6 are up to 12hours 
which increases its GI residence. As the concentration 
of carbopol 971P increased, the adhesion time is 
increase. The swelling index of the batch F3 and F6 is 
higher as compared to other batches. Drug release 
was found to be decreased as level of ethyl cellulose 
is increase and batch F2 having considerable swelling 
index and release of drug up to 12 hrs (98.85%). So it 
was concluded that Batch F2 can be taken as an ideal 
or optimized formulation of sustained release tablets 
for 12 hour release as it fulfills all the requirements 
for sustained release tablet. 
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